Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML.
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Bortezomib (Primary) ; Vorinostat (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 05 Jun 2012 Actual patient number is 16 according to ClinicalTrials.gov.
- 05 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.